ÂÜÀòÂÒÂ×

Dr. Scot Harper received his undergraduate degree from DePauw University and his doctoral degrees from Indiana University School of Medicine. He subsequently served on the faculty of the University of South Alabama College of Medicine, where he oversaw an extramurally funded research program in hypertension, stroke, and neoplasia.

He began his industry career with GlaxoSmithKline in medical affairs and new product development roles. He was recruited to Eli Lilly and Company to develop its oncology investigator-initiated clinical trial program and later became U.S. oncology medical director, followed by a role leading U.S. clinical research operations. He was recruited to Novartis Pharmaceuticals to head up North America clinical research operations and later became the CEO of a subsidiary, Novartis Clinical Operations, Inc., which provided clinical research services to all clinical development divisions within the company.

Following his retirement from Novartis, Dr. Harper became the head of clinical development at Endocyte, an oncology biotechnology company, leading its early phase clinical program. He is currently president of SLH Group, LLC, a life sciences consulting company.